AROC vs CRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AROC's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. Despite strong profitability metrics and robust earnings growth, elevated debt levels and weak technical momentum weigh on overall health. The stock trades above the Graham Number of $16.59 but below the growth-based intrinsic value of $44.55, suggesting a fair valuation given growth expectations. Analysts are bullish with a $31.56 target, though insider selling and a low technical trend score introduce caution.
CRK presents a contradictory profile: explosive growth and strong profitability contrasted with severe liquidity risks. The Piotroski F-Score of 4/9 indicates stable but mediocre financial health, while the current ratio of 0.49 signals a critical short-term liquidity deficit. While the stock trades near its Graham Number ($17.05), the intrinsic value ($10.01) and a bearish technical trend (0/100) suggest the market is pricing in significant risk. The massive YoY EPS growth (+610.5%) is the primary bullish driver, but it is offset by insider selling and poor short-term price momentum.
Compare Another Pair
Related Comparisons
AROC vs CRK: Head-to-Head Comparison
This page compares Archrock, Inc. (AROC) and Comstock Resources, Inc. (CRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.